• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Mineralys Therapeutics (MLYS) Reports Fresh Lorundrostat Data, Is The 63% Undervaluation Warranted?

    Simply Wall St·11/02/2026 02:37:04
    Listen to the news

    Mineralys Therapeutics (MLYS) has just tightened its grip on lorundrostat. Fresh Phase 2 Explore CKD data and a new deal with Tanabe Pharma now put the key intellectual property fully under Mineralys control.

    The recent data and licensing updates arrive after a sharp reset in expectations, with Mineralys Therapeutics posting a 1-day share price return of down 14.4%, a 30-day share price return of down 23.1% and a year-to-date share price return of down 49.1%, even though the 3-year total shareholder return is up about 1.2x overall. This suggests that long-term holders are still ahead, while short-term momentum has clearly faded.

    Spot opportunities beyond Mineralys Therapeutics by scanning a curated field of cardiorenal and hypertension players with the 34 healthcare AI stocks.

    For Mineralys Therapeutics, a near 50% slide this year sits against fresh trial wins and full lorundrostat control. Are investors reassessing the fundamentals, or just swinging with sentiment as valuation work begins?

    Most Popular Narrative: 63% Undervalued

    Analysts following Mineralys Therapeutics frame a fair value of $48.50 against a last close of $18.18, which places most of the debate on whether lorundrostat can eventually support the growth, margins and risk profile embedded in that model.

    Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

    See why 4 investors see Mineralys Therapeutics as 63% undervalued.

    Result: Fair Value of $48.50 (UNDERVALUED)

    Still, the narrative around Mineralys Therapeutics can change quickly if the NDA timeline slips or lorundrostat faces tougher than expected competition in aldosterone synthase inhibitors.

    Find out about the key risks to this Mineralys Therapeutics narrative.

    Next Steps

    Sentiment around Mineralys Therapeutics is clearly split. This is exactly when it helps to look past the headlines, check the underlying metrics, and decide where you stand using the fresh mix of caution and optimism captured in the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Mineralys Therapeutics?

    If Mineralys Therapeutics has your attention, do not stop there. Broader, high quality idea flow often separates a concentrated bet from a resilient portfolio.